uic-94003 has been researched along with amprenavir in 7 studies
| Studies (uic-94003) | Trials (uic-94003) | Recent Studies (post-2010) (uic-94003) | Studies (amprenavir) | Trials (amprenavir) | Recent Studies (post-2010) (amprenavir) |
|---|---|---|---|---|---|
| 18 | 0 | 4 | 555 | 91 | 94 |
| Protein | Taxonomy | uic-94003 (IC50) | amprenavir (IC50) |
|---|---|---|---|
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (BRU ISOLATE) | 0.027 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 2 (ISOLATE ROD) | 0.0026 | |
| Gag polyprotein | HIV-1 M:B_MN | 0.013 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 1 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.0558 | |
| Thromboxane-A synthase | Homo sapiens (human) | 6.727 | |
| Protease | Human immunodeficiency virus 1 | 0.1553 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buthod, J; Cho, H; Cho, W; Ghosh, AK; Holland, L; Hussain, KA; Kincaid, JF; Koo, Y; Krishnan, K; Rudall, C; Walters, DE | 1 |
| Azijn, H; de Bethune, MP; de Kock, HA; De Meyer, S; Jonckers, TH; King, NM; Pauwels, R; Peeters, A; Pille, GM; Prabu-Jeyabalan, M; Schiffer, CA; Surleraux, DL; Tahri, A; Verschueren, WG; Wigerinck, PB | 1 |
| Baldridge, A; Gemma, S; Ghosh, AK; Koh, Y; Kovalevsky, AY; Mitsuya, H; Wang, YF; Weber, IT | 1 |
| Ghosh, AK | 1 |
| Amano, M; Anderson, DD; Baldridge, A; Chumanevich, AA; Ghosh, AK; Hong, L; Koh, Y; Kovalevsky, AY; Kulkarni, S; Mitsuya, H; Tang, J; Tojo, Y; Wang, YF; Weber, IT | 1 |
| Freire, E; Ohtaka, H; Velázquez-Campoy, A; Xie, D | 1 |
| DeGoey, DA; Randolph, JT | 1 |
2 review(s) available for uic-94003 and amprenavir
| Article | Year |
|---|---|
Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Antiviral Agents; Aspartic Acid Endopeptidases; Biological Products; Darunavir; Drug Design; Drug Discovery; Drug Resistance, Viral; Enzyme Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Molecular Mimicry; Molecular Structure; Peptides; Structure-Activity Relationship; Sulfonamides | 2009 |
Peptidomimetic inhibitors of HIV protease.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane | 2004 |
5 other study(ies) available for uic-94003 and amprenavir
| Article | Year |
|---|---|
Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.
Topics: Cell Line; Drug Design; HIV Protease Inhibitors; Humans; Ligands; Models, Chemical; Saquinavir; Sulfonamides | 1998 |
Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
Topics: Administration, Oral; Animals; Biological Availability; Cell Line; Crystallography, X-Ray; Darunavir; Dogs; Drug Resistance, Multiple, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Microsomes, Liver; Models, Molecular; Molecular Conformation; Mutation; Rats; Stereoisomerism; Structure-Activity Relationship; Sulfonamides; Thermodynamics | 2005 |
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
Topics: Antiviral Agents; Cell Survival; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Design; Ethers, Cyclic; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hydrogen Bonding; Ligands; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Polyesters; Stereoisomerism; Structure-Activity Relationship; T-Lymphocytes; Water | 2008 |
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
Topics: Anti-HIV Agents; Cell Line; Crystallography, X-Ray; Drug Design; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Macrocyclic Compounds; Models, Molecular; Molecular Conformation; Mutation | 2009 |
Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
Topics: Binding Sites; Calorimetry; Carbamates; Drug Design; Drug Resistance, Viral; Escherichia coli; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Kinetics; Models, Molecular; Mutagenesis, Site-Directed; Protein Binding; Sulfonamides; Thermodynamics; Urethane | 2002 |